Advanced Accelerator Applications is reimagining nuclear medicine and cancer care. Its mission is to transform patients’ lives by developing and delivering targeted radioligand therapies and precision imaging radioligands for oncology.
AAA is the radioactive ligand subsidiary of Novartis, which currently markets two targeted radioligand therapies in oncology, as well as several precision imaging products. Located not far from the beautiful Lake Geneva, this AAA site serves as a collaboration hub for many corporate functions.
Advanced Accelerator Applications International has been based in Geneva since 2014.